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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the *Coronaviridae* family and *Betacoronaviru*s genus, is the causative agent of pandemic coronavirus disease-2019 (COVID-19). In Bangladesh, the rate of positive cases and the death toll from COVID-19 are increasing at an alarming rate (<https://corona.gov.bd/>). To understand the genomic characteristics of SARS-CoV-2 in Bangladesh, several isolates have been sequenced and deposited in GISAID (<https://www.gisaid.org/>). However, those isolates have been sequenced using a next-generation sequencing platform, except for the one we are reporting. In this study, we sequenced the viral genome by Sanger sequencing technology, which is a gold standard method and is necessary for thorough genomic analysis ([@B1]).

The isolate (SARS-CoV-2/human/BGD/NIB_01/2020) was collected from an oropharyngeal specimen on 11 May 2020. The patient was a 28-year-old saleswoman who tested positive (via reverse transcriptase PCR \[RT-PCR\]) for COVID-19 with symptoms of cough, mild fever, and throat congestion. (all applicable international, national, and/or institutional guidelines for the care and use of animals were followed; ethical approval number NIBREC2020-01). The viral RNA was extracted directly from the patient's specimen using the PureLink viral RNA/DNA minikit (Invitrogen). The viral RNA was then converted into cDNA using a SuperScript VILO cDNA synthesis kit (Invitrogen).

To cover the whole genome of the virus, 48 pairs of primers were designed by following two conditions: (i) their sequence is conserved among all the available SARS-CoV-2 isolates, and (ii) the terminal of the amplicons will overlap the adjacent amplicon ([Table 1](#tab1){ref-type="table"}). These primers underwent PCR and generated 96 amplicons, which were visualized using 1.5% agarose gel electrophoresis. The PCR products were then purified using the PureLink PCR purification kit (Thermo Fisher Scientific, USA). These purified amplicons were finally sequenced with 2× coverage using the Sanger dideoxy method by "ABI 3500" with a BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems, USA).

###### 

Information about primers, amplicon size, and overlapping length

  Amplicon   Primer    Sequence                 Product size (bp)   Overlapping length (bp)
  ---------- --------- ------------------------ ------------------- -------------------------
  1          Forward   AGGTTTATACCTTCCCAGG      765                 131
  1          Reverse   CACCACTGCTATGTTTAGTG                         
  2          Forward   CGCAAGGTTCTTCTTCGTA      797                 
  2          Reverse   AGACTATGCTCAGGTCCTAC     100                 
  3          Forward   AAGAAGGTGCCACTACTTG      794                 
  3          Reverse   GTTAGTTAGCCACTGCGAA      114                 
  4          Forward   ACTGAGACTCATTGATGCTA     788                 
  4          Reverse   TCACACTCTTGTAACCTTGC     130                 
  5          Forward   AGAAAAGTACTGTGCCCTTG     783                 
  5          Reverse   ACCACTGTTGGTTTTACCTT     131                 
  6          Forward   GATGGAACTTACACCAGTTG     781                 
  6          Reverse   GTCACTAACAAGAGTGGCAG     110                 
  7          Forward   GAAGAAGTTACAACAACTCTGG   718                 
  7          Reverse   AAACTGTAGCTGGCACTTTG     136                 
  8          Forward   TGTAGCGTCACTTATCAACA     746                 
  8          Reverse   CAGTGGCAAGATAACAGTTG     158                 
  9          Forward   CTCTACGTGTTGAGGCTTTT     720                 
  9          Reverse   CATCCGTAATAGGACCTTTGT    130                 
  10         Forward   TTGTGCTAGTGAGTACACTG     760                 
  10         Reverse   AATGTCTCCTACAACTTCGG     150                 
  11         Forward   TGATGTACTGAAGTCAGAGG     737                 
  11         Reverse   AATAGCCTTCTCTGTAACCAG    90                  
  12         Forward   TTCTTTAATCTACTCAACCGC    706                 
  12         Reverse   CTGTAGTGACAAGTCTCTCG     118                 
  13         Forward   ATGCTAATGGAGGTAAAGGC     701                 
  13         Reverse   ACAACTATCGCCAGTAACTTC    115                 
  14         Forward   CTTTTATTTCAGCAGCTCGG     714                 
  14         Reverse   GTGCGTAATATCGTGCCA       133                 
  15         Forward   GCTGATTTTGACACATGGTT     812                 
  15         Reverse   GGTAAGAATGAGTAAACTGGTG   196                 
  16         Forward   CCTATTGGTGCTTTGGACATA    727                 
  16         Reverse   AACCCTCAACTTTACCAGATG    146                 
  17         Forward   CTTGTTGTCATCTCGCAAAG     767                 
  17         Reverse   TCGATTGAGAAACCACCTGT     112                 
  18         Forward   TTGTTGACAGGCAAACAGC      770                 
  18         Reverse   ACCATCATCATACACAGTTCT    121                 
  19         Forward   TGACATGGTTGGATATGGTTG    794                 
  19         Reverse   GTTTATGTCTACAGCACCCT     172                 
  20         Forward   AATTGTGGGCTCAATGTGT      787                 
  20         Reverse   GCAACAGGACTAAGCTCATTA    155                 
  21         Forward   GGAAATCCAACAGGTTGTAGA    795                 
  21         Reverse   ACAGGGTCATTAGCACAAGT     90                  
  22         Forward   GTTGCCACATAGATCATCCAA    790                 
  22         Reverse   AACAATACCAGCATTTCGC      233                 
  23         Forward   GCAGACCTCGTCTATGCTTT     813                 
  23         Reverse   GCACGTAGTGCGTTTATCT      147                 
  24         Forward   CCACTTCAGAGAGCTAGGTG     782                 
  24         Reverse   GTGAGGGTTTTCTACATCACT    114                 
  25         Forward   ATTGAAATCAATAGCCGCCA     775                 
  25         Reverse   ATCTGGGTAAGGAAGGTACA     117                 
  26         Forward   GTCTGAAGCAAAATGTTGGA     805                 
  26         Reverse   GAGTCTTTCAGTACAGGTGTT    142                 
  27         Forward   TGTGTGCTAATGGACAAGTT     784                 
  27         Reverse   TCAAAACACTCTACACGAGC     132                 
  28         Forward   CTTCTGCTCGCATAGTGTAT     769                 
  28         Reverse   CAAGAGTGAGCTGTTTCAGT     191                 
  29         Forward   AATAGGCGTGGTAAGAGAAT     790                 
  29         Reverse   GTACATAAGTGGTATGAGGTGT   139                 
  30         Forward   AGCTAGGTTTTTCTACAGGTG    756                 
  30         Reverse   CTTTGTCACTACAAGGCTGT     152                 
  31         Forward   GTAGAAAGGTTCAACACATGG    733                 
  31         Reverse   ATAGAAACTGGTACTTCACCC    144                 
  32         Forward   GCTTTAGCTTGTGGGTTTAC     808                 
  32         Reverse   CCACCTAACTGACTATGACT     139                 
  33         Forward   CAAGAATTTAAACCCAGGAG     758                 
  33         Reverse   GCATCAGAGACAAAGTCATT     155                 
  34         Forward   CACATTAACATTAGCTGTACCC   781                 
  34         Reverse   TGACTAGAGACTAGTGGCA      182                 
  35         Forward   AAGGGGTACTGCTGTTATGT     775                 
  35         Reverse   TTAATAGGCGTGTGCTTAGA     116                 
  36         Forward   TCAGCCTTTTCTTATGGACC     794                 
  36         Reverse   TCCAAGCTATAACGCAGC       104                 
  37         Forward   TTAGAGGTGATGAAGTCAGA     760                 
  37         Reverse   TGTTCAGCCCCTATTAAACA     149                 
  38         Forward   TAACCAGGTTGCTGTTCTTT     797                 
  38         Reverse   CAATCATTTCATCTGTGAGCA    191                 
  39         Forward   CAGATCCATCAAAACCAAGC     771                 
  39         Reverse   GCAAGAAGACTACACCATGA     137                 
  40         Forward   TCAGAGCTTCTGCTAATCTTG    759                 
  40         Reverse   GTAATTTGACTCCTTTGAGC     137                 
  41         Forward   TTGCCATAGTAATGGTGACA     798                 
  41         Reverse   AGCTGGTAATAGTCTGAAGTG    120                 
  42         Forward   GCACAACAAGTCCTATTTCT     784                 
  42         Reverse   CCATAACAGCCAGAGGAAAA     170                 
  43         Forward   GCAGATTCCAACGGTACT       707                 
  43         Reverse   TAGTAACCTGAAAGTCAACG     117                 
  44         Forward   GCTACAGGATTGGCAACTAT     785                 
  44         Reverse   TTTCATGTTCGTTTAGGCGT     174                 
  45         Forward   CACTTTGCTTCACACTCAAA     791                 
  45         Reverse   TCTGGACTGCTATTGGTGTT     180                 
  46         Forward   CAGATTCAACTGGCAGTAAC     793                 
  46         Reverse   TTTCCTTGGGTTTGTTCTGG     187                 
  47         Forward   CTGCTTGACAGATTGAACCA     698                 
  47         Reverse   CTTGTGCTATGTAGTTACGAGA   242                 
  48         Forward   ATGAAACTCAAGCCTTACCG     518                 
  48         Reverse   CCTTTCGTGCAGGTCAATA                          
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The raw reads were assembled using DNA Sequence Assembler version 4 (2013) (Heracle BioSoft) and verified with SeqMan Pro version 14.1 (DNAStar, Madison, WI). After assembly, 48 contigs with 94 overlapping regions were obtained. These overlapping regions were visualized using CLC Genomics Workbench version 20.0.4 and merged with EMBOSS: merger ([@B2]).

The assembled viral genome consists of a single-stranded positive (+) RNA that is 29,724 nucleotides long. The NCBI BLASTN program ([@B3]) showed that the genome was mostly similar to SARS-CoV-2/human/BGD/CHRF_0001/2020 (GenBank accession number [MT476385.1](https://www.ncbi.nlm.nih.gov/nuccore/MT476385.1)). From NCBI, the FASTA sequences of 7 mostly similar genomes from Bangladesh, India, Sri Lanka, and the United States were taken along with the reference genome. Another 16 genomes of SARS-CoV-2 that were isolated in Bangladesh were collected from GISAID (<https://www.gisaid.org/>). The genomes were aligned with MAFFT version 7 using default parameters ([@B4]). The phylogenetic tree was constructed using FastTree version 2.1.10 ([@B5]) through the Galaxy platform ([@B6]). Here, the tree was built by nucleotide alignment using the generalized time-reversable model (GTR) plus the CAT nucleotide evolution model (GTR+CAT). The tree was visualized using iTOL ([@B7]), where the tree structure was rerooted on the position of reference isolate SARS-CoV-2 Wuhan-Hu-1.

The genome has 8 nucleotide differences from the closest isolate. Interestingly, except for isolate SARS-CoV-2/human/BGD/CHRF0001/2020, the other strains of SARS-CoV-2 from Bangladesh showed separate clades and distant genetic relations. The tree also demonstrated that our viral genome and three isolates from the United States share an ancestor ([Fig. 1](#fig1){ref-type="fig"}).

![Phylogenetic analysis of the SARS-CoV-2/human/BGD/NIB_01/2020 isolate. Nucleotide alignment and the GTR+CAT nucleotide evolution model was applied to construct the tree. The tree was visualized using i-TOL. Here, the *x* axis represents the tree scale. A scale bar with a 0.0001 value is given on the top. The genome (labeled in red) shares a common ancestor with some isolates from the United States.](MRA.00626-20-f0001){#fig1}
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The complete nucleotide sequence of this SARS-CoV-2 isolate (SARS-CoV-2/human/BGD/NIB_01/2020) has been deposited in GenBank under the accession number [MT509958](https://www.ncbi.nlm.nih.gov/nuccore/MT509958).
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